KBTBD7 promotes non-small cell lung carcinoma progression by enhancing ubiquitin-dependent degradation of PTEN.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
12 2022
Historique:
revised: 12 03 2022
received: 05 12 2021
accepted: 01 04 2022
pubmed: 3 5 2022
medline: 15 12 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

The Kelch repeat and BTB domain containing 7 (KBTBD7) was first cloned in 2010. Its function as a transcriptional activator and a substrate adaptor during the ubiquitination process was soon found. KBTBD7 was shown to be involved in excessive inflammation after myocardial infarction, brain development, and neurofibromin stability. However, studies on the role of KBTBD7 in solid tumors, especially lung cancer, are still lacking. Therefore, in this study, we investigate the role of KBTBD7 in non-small cell lung cancer (NSCLC). Immunohistochemical staining of 104 paired NSCLC and peritumoral normal specimens indicated that KBTBD7 was highly expressed in NSCLC tissues and positively correlated with the histological type, P-TNM stage, lymph node metastasis, and tumor size. KBTBD7 was also well-expressed in NSCLC cell lines, and downregulation of KBTBD7 resulted in inhibition of NSCLC cell proliferation and invasion. Further investigation showed that KBTBD7 enhanced ubiquitin-dependent degradation of PTEN, thus activating EGFR/PI3K/AKT signaling and promoting NSCLC cell proliferation and invasion by regulating CCNE1, CDK4, P27, ZEB-1, Claudin-1, ROCK1, MMP-9, and E-cadherin protein levels. Our results indicate that KBTBD7 may be a potential therapeutic target for the treatment of NSCLC.

Identifiants

pubmed: 35499228
doi: 10.1002/cam4.4794
pmc: PMC9741964
doi:

Substances chimiques

Phosphatidylinositol 3-Kinases EC 2.7.1.-
Ubiquitin 0
PTEN Phosphohydrolase EC 3.1.3.67
ROCK1 protein, human EC 2.7.11.1
rho-Associated Kinases EC 2.7.11.1
PTEN protein, human EC 3.1.3.67
KBTBD7 protein, human 0
Intracellular Signaling Peptides and Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4544-4554

Informations de copyright

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Mol Cell. 2015 Mar 19;57(6):995-1010
pubmed: 25684205
Signal Transduct Target Ther. 2020 Feb 29;5(1):11
pubmed: 32296023
CA Cancer J Clin. 2020 Aug 25;:
pubmed: 32964460
BMB Rep. 2010 Jan;43(1):17-22
pubmed: 20132730
Cancer Commun (Lond). 2019 Mar 2;39(1):7
pubmed: 30823937
Nat Rev Clin Oncol. 2010 Sep;7(9):493-507
pubmed: 20551942
Nat Rev Cancer. 2011 Apr;11(4):289-301
pubmed: 21430697
Cell. 2000 Feb 18;100(4):387-90
pubmed: 10693755
Nat Commun. 2016 Feb 12;7:10689
pubmed: 26869029
J Cell Mol Med. 2018 Oct;22(10):5020-5028
pubmed: 30079558
Cancer Causes Control. 2013 Mar;24(3):439-50
pubmed: 23314675
Oncologist. 2013;18(10):1083-90
pubmed: 24037976
J Cell Mol Med. 2020 Jun;24(12):6644-6657
pubmed: 32337844
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6459-64
pubmed: 20308550
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncol Rep. 2016 Jan;35(1):530-7
pubmed: 26531778
Clin Cancer Res. 2012 Jan 15;18(2):400-7
pubmed: 22252256
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
J Exp Clin Cancer Res. 2019 Feb 12;38(1):72
pubmed: 30755245
Cancer Med. 2022 Dec;11(23):4544-4554
pubmed: 35499228
Cell. 2008 May 2;133(3):403-14
pubmed: 18455982
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
J Exp Clin Cancer Res. 2018 Aug 13;37(1):189
pubmed: 30103781
Cancer Cell. 2009 Apr 7;15(4):304-14
pubmed: 19345329
Acta Neuropathol. 2020 Sep;140(3):377-396
pubmed: 32572597
Cell Death Dis. 2018 Jul 10;9(7):769
pubmed: 29991775
Cancer Sci. 2018 Apr;109(4):1055-1065
pubmed: 29451718
Am J Cancer Res. 2015 Aug 15;5(9):2892-911
pubmed: 26609494

Auteurs

Zifang Zou (Z)

Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Bo Zhang (B)

Department of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.

Zhihan Li (Z)

Department of Pathology, The Second Hospital of Dalian Medical University, Dalian, People's Republic of China.

Lei Lei (L)

Department of Pathology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Guanghao Sun (G)

Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Xizi Jiang (X)

Department of Pathology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Jingqian Guan (J)

Department of Pathology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Yao Zhang (Y)

Department of Pathology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Shun Xu (S)

Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Qingchang Li (Q)

Department of Pathology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH